479PSafety profile of tepotinib in patients with advanced solid tumors: Pooled analysis of phase I and II data

ConclusionsTepotinib demonstrated an acceptable safety profile across a range of tumor types and is being developed in NSCLC as monotherapy and in combination. Further characterization of peripheral edema is ongoing. Table:479PN  = 228Any Grade (≥10%)Grade ≥3 (≥2%)Any TRAE, n (%)172 (75.4)52 (22.8)Peripheral edema77 (33.8)8 (3.5)Diarrhea45 (19.7)4 (1.8)Fatigue34 (14.9)3 (1.3)Nausea29 (12.7)0 (0)Decreased appetite27 (11.8)0 (0)Increased lipase13 (5.7)9 (3.9)Increased AST11 (4.8)5 (2.2)Clinical trial identificationNCT01014936, NCT01832506, NCT01988493, NCT02115373, NCT02864992.Editorial acknowledgementMedical writing assistance (funded by Merck Healthcare KGaA, Darmstadt, Germany) was provided by Matthew deSchoolmeester, PhD of Bioscript Science (Macclesfield, UK).Legal entity responsible for the studyMerck KGaA.FundingMerck KGaA.DisclosureT. Decaens: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Travel / Accommodation / Expenses: Bayer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy: IPSEN; Honoraria (self), Travel / Accommodation / Expenses: Gilead; Honoraria (self), Travel / Accommodation / Expenses: Abbvie; Honoraria (self): Sanofi; Advisory / Consultancy: SITEX; Research grant / Funding (institution): ArQule; Research grant / Funding (institution): Genoscience Pharma; Research grant / Funding (institution), Travel / Accommodati...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research